Children's Hospital of Philadelphia spinoff investment pays off big with Roche acquisition

The CHOP Foundation had ownership of nearly 4 million shares, or about 11%, of the Philadelphia-based Spark. (Children's Hospital of Philadelphia)

Children's Hospital of Philadelphia was among the winners when pharmaceutical giant Roche announced plans this week to acquire gene therapy company Spark Therapeutics for $4.8 billion.

SEC filings show the CHOP Foundation had ownership of nearly 4 million shares, or about 11%, of the Philadelphia-based Spark. With the all-cash deal of $114.50 a share, that works out to more than a $456 million payoff for the foundation. As Bloomberg reports, that is in addition to an estimated $285 million the foundation made in earlier share sales.

It turned out to be a particularly lucrative return on what was an original investment of $50 million by the CHOP Foundation. 

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

Spark spun out of CHOP in 2013 around gene therapy technology aimed at treating a rare and inherited form of blindness that affects children. It has a pipeline of nine investigational gene therapies, including three gene therapies in clinical trials.

RELATED: Children's Hospital of Philadelphia goes global in partnership with United Arab Emirates

SEC filings show CHOP has had ongoing collaborations with Spark including licensing, research and clinical trial agreements. Officials say Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group.

The deal is also expected to bring big payouts to several officials affiliated with CHOP.

Spark's leadership includes CEO and Co-Founder Jeffrey D. Marrazzo, who formerly served as an independent consultant to CHOP, and Spark's President Katherine High, whose studies at CHOP established the first proof of principle of gene therapy for hemophilia in preclinical models, owned 662,613 and 370,021 shares in the company, respectively.

Board chairman Steven M. Altschuler, M.D., the former CEO of CHOP and its foundation, owned 64,711 shares.

Suggested Articles

Humana filed suit Friday against more than a dozen generic drugmakers alleging the companies engaged in price fixing.

Ochsner Health System is partnering with Color to launch a population health pilot program to integrate genetic information into preventive care.

Medicare Advantage open enrollment kicked off last week, and insurers are taking new approaches to marketing a slate of supplemental benefit options.